Novo Nordisk A/S (NOVOB80)
Thailand Exchange · Thailand · prices in THB · close of 20 Oct 2026
Key indicators
| Last close | THB 1.290 |
|---|---|
| 52-week range | 1.080 – 1.948 |
| Return, 1 month / 3 months | −8.5% / −21.8% |
| Return, 1 year / 3 years | −27.3% / – |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 48.4% |
| Worst drawdown (1 year) | -41.0% |
| Average daily value traded | 4.99M THB |
| Dividend yield | 3.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novo Nordisk is a pharmaceutical company based in Denmark that develops and makes medicines for people with diabetes and other chronic conditions. Its main products are insulin preparations and other injectable diabetes treatments, along with hormone therapies and medicines for bleeding disorders. It supplies healthcare professionals, hospitals and pharmacies in many countries, and it also produces delivery devices such as injection pens for its treatments.
Novo Nordisk A/S trades under the code NOVOB80 on the Thailand Exchange in Thailand, with its price quoted in Thai baht (THB). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novo Nordisk A/S (NOVOB80) trades on the Thailand Exchange in Thailand. It last closed at THB 1.290 on 20 October 2026.
Its price-based Market X-Ray is 32 out of 100 (a weak price profile), ranking 1,013 of 1,348 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.3% and over the last three months it fell 21.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Thailand Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 21 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.2% | ||
| From 52-week high | -33.1% | ||
| Momentum | 24 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -21.8% | ||
| 6-month return | 2.9% | ||
| 12-month return, skipping the last month | -20.5% | ||
| Stability (higher is calmer) | 27 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 48.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.0% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 4.99M THB | ||
| Zero-volume days | 5.0% | ||
| Income | 26 · Weak | Dividend is small or irregular. | |
| Dividend yield | 3.2% | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −8.5% |
| 3 months | −21.8% |
| 6 months | +2.9% |
| 1 year | −27.3% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 1.420 / 1.452 |
|---|---|
| Golden / death cross (60 days) | Death, 7 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.036 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | DKK 0.0133 |
| 27 Mar 2026 | DKK 0.0279 |
| 15 Aug 2025 | DKK 0.0187 |
| 28 Mar 2025 | DKK 1.2235 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Thailand Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.